Folate receptor targeted delivery of siRNA and paclitaxel to ovarian cancer cells via folate conjugated triblock copolymer to overcome TLR4 driven chemotherapy resistance

Biomacromolecules

Volumn 17, Issue 1, 2016, Pages 76-87

  Jones, Steven K ^a   Lizzio, Vincent ^a,b   Merkel, Olivia M ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCK COPOLYMERS; CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; ELECTROPHORESIS; GRAFTING (CHEMICAL); HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; INTERFERONS; LIGHT SCATTERING; LIGHT TRANSMISSION; ORGANIC POLYMERS; POLYCAPROLACTONE; POLYETHYLENE OXIDES; POLYMERS; PROTEINS; RNA; TRANSMISSION ELECTRON MICROSCOPY;

LUCIFERASE ASSAYS; OVARIAN CANCER CELLS; POLYETHYLENIMINES; RELIABLE DELIVERY; TARGETED DELIVERY; THERAPEUTIC PROTEIN; TOLL-LIKE RECEPTOR 4; WESTERN-BLOT ANALYSIS;

POLYETHYLENE GLYCOLS;

COPOLYMER; FOLATE RECEPTOR; FOLIC ACID; MACROGOL; PACLITAXEL; POLYCAPROLACTONE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; FOLATE RECEPTOR 1; POLYESTER; POLYETHYLENIMINE-GRAFT-POLYCAPROLACTONE-BLOCK-POLY(ETHYLENE GLYCOL); POLYMER; TLR4 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESEARCH; CANCER RESISTANCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; MICELLE; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; OVARY CANCER; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; POLYESTERS; POLYETHYLENEIMINE; POLYMERS; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 4;

EID: 84954100796     PISSN: 15257797     EISSN: 15264602     Source Type: Journal    
DOI: 10.1021/acs.biomac.5b01189     Document Type: Article

References (55)

1. Markert, S.; Lassmann, S.; Gabriel, B.; Klar, M.; Werner, M.; Gitsch, G.; Kratz, F.; Hasenburg, A. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue Anticancer Res. 2008, 28 (6A) 3567-72
2. Parker, N.; Turk, M. J.; Westrick, E.; Lewis, J. D.; Low, P. S.; Leamon, C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay Anal. Biochem. 2005, 338 (2) 284-93 10.1016/j.ab.2004.12.026
3. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications Cancer 1994, 73 (9) 2432-43 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
4. NIH National Cancer Institute What you need to know about Ovarian Cancer. NIH Publication 06-1561, National Cancer Institute: Bethesda, MD, 2006.
5. Institute, N. C. Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. http://www.easterncarolinawomens.com/womens-health/hw-view.php?DOCHWID=ncicdr0000062963.
6. Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 2013, 73 (8) 2412-7 10.1158/0008-5472.CAN-12-4561
7. Ledermann, J. A.; Kristeleit, R. S. Optimal treatment for relapsing ovarian cancer Ann. Oncol 2010, 21 (Suppl 7) vii218-22 10.1093/annonc/mdq377
8. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2 (12) 751-60 10.1038/nnano.2007.387
9. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65 (1-2) 271-84 10.1016/S0168-3659(99)00248-5
10. Leamon, C. P. Folate-targeted drug strategies for the treatment of cancer Curr. Opin. Investig. Drugs 2008, 9 (12) 1277-86
11. Benoit, D. S.; Srinivasan, S.; Shubin, A. D.; Stayton, P. S. Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery Biomacromolecules 2011, 12 (7) 2708-14 10.1021/bm200485b
12. Liu, Y.; Li, K.; Pan, J.; Liu, B.; Feng, S. S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel Biomaterials 2010, 31 (2) 330-8 10.1016/j.biomaterials.2009.09.036
13. Morris, R. T.; Joyrich, R. N.; Naumann, R. W.; Shah, N. P.; Maurer, A. H.; Strauss, H. W.; Uszler, J. M.; Symanowski, J. T.; Ellis, P. R.; Harb, W. A. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide) Ann. Oncol 2014, 25 (4) 852-8 10.1093/annonc/mdu024
14. Vlahov, I. R.; Leamon, C. P. Engineering folate-drug conjugates to target cancer: from chemistry to clinic Bioconjugate Chem. 2012, 23 (7) 1357-69 10.1021/bc2005522
15. Wang, X.; Li, S.; Shi, Y.; Chuan, X.; Li, J.; Zhong, T.; Zhang, H.; Dai, W.; He, B.; Zhang, Q. The development of site-specific drug delivery nanocarriers based on receptor mediation J. Controlled Release 2014, 193, 139-53 10.1016/j.jconrel.2014.05.028
16. Lu, Y.; Low, P. S. Folate-mediated delivery of macromolecular anticancertherapeutic agents Adv. Drug Delivery Rev. 2002, 54, 675-693 10.1016/S0169-409X(02)00042-X
17. Huang, Y. H.; Bao, Y.; Peng, W.; Goldberg, M.; Love, K.; Bumcrot, D. A.; Cole, G.; Langer, R.; Anderson, D. G.; Sawicki, J. A. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (9) 3426-30 10.1073/pnas.0813348106
18. Shahzad, M. M.; Lu, C.; Lee, J. W.; Stone, R. L.; Mitra, R.; Mangala, L. S.; Lu, Y.; Baggerly, K. A.; Danes, C. G.; Nick, A. M.; Halder, J.; Kim, H. S.; Vivas-Mejia, P.; Landen, C. N.; Lopez-Berestein, G.; Coleman, R. L.; Sood, A. K. Dual targeting of EphA2 and FAK in ovarian carcinoma Cancer Biol. Ther. 2009, 8 (11) 1027-34 10.4161/cbt.8.11.8523
19. Li, L.; Gu, W.; Chen, J.; Chen, W.; Xu, Z. P. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles Biomaterials 2014, 35 (10) 3331-9 10.1016/j.biomaterials.2013.12.095
20. Shen, J.; Yin, Q.; Chen, L.; Zhang, Z.; Li, Y. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer Biomaterials 2012, 33 (33) 8613-24 10.1016/j.biomaterials.2012.08.007
21. Ghosh, S. K.; Yigit, M. V.; Uchida, M.; Ross, A. W.; Barteneva, N.; Moore, A.; Medarova, Z. Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma Int. J. Cancer 2014, 134 (7) 1758-66 10.1002/ijc.28499
22. Sourbier, C. Ovarian cancer: emerging molecular-targeted therapies Biologics 2012, 6, 147-54 10.2147/BTT.S24155
23. Goldberg, M. S.; Xing, D.; Ren, Y.; Orsulic, S.; Bhatia, S. N.; Sharp, P. A. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (2) 745-50 10.1073/pnas.1016538108
24. Wang, A. C.; Su, Q. B.; Wu, F. X.; Zhang, X. L.; Liu, P. S. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells Eur. J. Clin. Invest. 2009, 39 (2) 157-64 10.1111/j.1365-2362.2008.02070.x
25. Szajnik, M.; Szczepanski, M. J.; Czystowska, M.; Elishaev, E.; Mandapathil, M.; Nowak-Markwitz, E.; Spaczynski, M.; Whiteside, T. L. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer Oncogene 2009, 28 (49) 4353-63 10.1038/onc.2009.289
26. Kelly, M. G.; Alvero, A. B.; Chen, R.; Silasi, D. A.; Abrahams, V. M.; Chan, S.; Visintin, I.; Rutherford, T.; Mor, G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer Cancer Res. 2006, 66 (7) 3859-68 10.1158/0008-5472.CAN-05-3948
27. Yin, Q.; Shen, J.; Chen, L.; Zhang, Z.; Gu, W.; Li, Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters) Biomaterials 2012, 33 (27) 6495-506 10.1016/j.biomaterials.2012.05.039
28. Endres, T.; Zheng, M.; Kilic, A.; Turowska, A.; Beck-Broichsitter, M.; Renz, H.; Merkel, O. M.; Kissel, T. Amphiphilic biodegradable PEG-PCL-PEI triblock copolymers for FRET-capable in vitro and in vivo delivery of siRNA and quantum dots Mol. Pharmaceutics 2014, 11 (4) 1273-81 10.1021/mp400744a
29. Zheng, M.; Liu, Y.; Samsonova, O.; Endres, T.; Merkel, O.; Kissel, T. Amphiphilic and biodegradable hy-PEI-g-PCL-b-PEG copolymers efficiently mediate transgene expression depending on their graft density Int. J. Pharm. 2012, 427 (1) 80-7 10.1016/j.ijpharm.2011.05.017
30. Yu Liu, J. N.; Steele, T.; Merkel, O.; Kissel, T. A new synthesis method and degradation of hyper-branched polyethylenimine grafted polycaprolactone block mono-methoxyl poly (ethylene glycol) copolymers (hy-PEI-g-PCL-b-mPEG) as potential DNA delivery vectors Polymer 2009, 50 (16) 3895-3904 10.1016/j.polymer.2009.06.043
31. Zheng, M.; Librizzi, D.; Kilic, A.; Liu, Y.; Renz, H.; Merkel, O. M.; Kissel, T. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers Biomaterials 2012, 33 (27) 6551-8 10.1016/j.biomaterials.2012.05.055
32. Akhtar, S. Non-viral cancer gene therapy: beyond delivery Gene Ther. 2006, 13 (9) 739-40 10.1038/sj.gt.3302692
33. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Delivery Rev. 2014, 66, 2-25 10.1016/j.addr.2013.11.009
34. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides Mol. Pharmaceutics 2009, 6 (3) 686-95 10.1021/mp900093r
35. Merkel, O. M.; Kissel, T. Nonviral pulmonary delivery of siRNA Acc. Chem. Res. 2012, 45 (7) 961-70 10.1021/ar200110p
36. Liu, L.; Zheng, M.; Renette, T.; Kissel, T. Modular Synthesis of Folate Conjugated Ternary Copolymers: Polyethylenimine-graft-Polycaprolactone-block-Poly(ethylene glycol)-Folae for Targeted Gene Delivery Bioconjugate Chem. 2012, 23, 1211-1220 10.1021/bc300025d
37. Merkel, O. M.; Beyerle, A.; Beckmann, B. M.; Zheng, M.; Hartmann, R. K.; Stoger, T.; Kissel, T. H. Polymer-related off-target effects in non-viral siRNA delivery Biomaterials 2011, 32 (9) 2388-98 10.1016/j.biomaterials.2010.11.081
38. Storey, R. F.; Sherman, J. W. Kinetics and Mechanism of the Stannous Octoate-Catalyzed Bulk Polymerization of e-Caprolactone Macromolecules 2002, 35, 1504-1512 10.1021/ma010986c
39. Hans, M.; Gasteier, P.; Keul, H.; Moeller, M. Ring-Opening Polymerization of e-Caprolactone by Means of Mono-and Multifunctional Initiators: Comparison of Chemical and Enzymatic Catalysis Macromolecules 2002, 39, 3184-3193 10.1021/ma052657g
40. Merkel, O. M.; Beyerle, A.; Librizzi, D.; Pfestroff, A.; Behr, T. M.; Sproat, B.; Barth, P. J.; Kissel, T. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance Mol. Pharmaceutics 2009, 6 (4) 1246-60 10.1021/mp900107v
41. Elsayed, M.; Corrand, V.; Kolhatkar, V.; Xie, Y.; Kim, N. H.; Kolhatkar, R.; Merkel, O. M. Influence of oligospermines architecture on their suitability for siRNA delivery Biomacromolecules 2014, 15 (4) 1299-310 10.1021/bm401849d
42. Merkel, O. M.; Librizzi, D.; Pfestroff, A.; Schurrat, T.; Buyens, K.; Sanders, N. N.; De Smedt, S. C.; Behe, M.; Kissel, T. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging J. Controlled Release 2009, 138 (2) 148-59 10.1016/j.jconrel.2009.05.016
43. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 2010, 31 (13) 3657-3666 10.1016/j.biomaterials.2010.01.065
44. Storm, G.; Belliot, S. O.; Daemen, T.; Lasic, D. D. Lasic, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system Adv. Drug Delivery Rev. 1995, 17, 31 10.1016/0169-409X(95)00039-A
45. Sons, J. W. Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications. John Wiley and Sons, Inc.: Hoboken, NJ, 2012.
46. Jiang, W. K.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 2008, 3, 145-150 10.1038/nnano.2008.30
47. Lauweryns, J. M.; Baert, J. H. Alveolar clearance and the role of the pulmonary lymphatics Am. Rev. Respir. Dis. 1977, 115 (4) 625-683
48. Li, J. M.; Wang, Y. Y.; Zhang, W.; Su, H.; Ji, L. N.; Mao, Z. W. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-beta-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA Int. J. Nanomed. 2013, 8, 2101-17 10.2147/IJN.S42440
49. Teow, Y.; Valiyaveettil, S. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles Nanoscale 2010, 2 (12) 2607-13 10.1039/c0nr00204f
50. Yu, B.; Tang, C.; Yin, C. Enhanced antitumor efficacy of folate modified amphiphilic nanoparticles through co-delivery of chemotherapeutic drugs and genes Biomaterials 2014, 35 (24) 6369-78 10.1016/j.biomaterials.2014.04.095
51. Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery Mol. Pharmacol. 2004, 66 (6) 1406-14 10.1124/mol.104.003723
52. Arima, H.; Yoshimatsu, A.; Ikeda, H.; Ohyama, A.; Motoyama, K.; Higashi, T.; Tsuchiya, A.; Niidome, T.; Katayama, Y.; Hattori, K.; Takeuchi, T. Folate-PEG-appended dendrimer conjugate with alpha-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier Mol. Pharmaceutics 2012, 9 (9) 2591-604 10.1021/mp300188f
53. Fernandes, J. C.; Qiu, X.; Winnik, F. M.; Benderdour, M.; Zhang, X.; Dai, K.; Shi, Q. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies Int. J. Nanomed. 2012, 7, 5833-45 10.2147/IJN.S35567
54. Van Rompaey, E.; Engelborghs, Y.; Sanders, N.; De Smedt, S. C.; Demeester, J. Interactions between oligonucleotides and cationic polymers investigated by fluorescence correlation spectroscopy Pharm. Res. 2001, 18 (7) 928-36 10.1023/A:1010975908915
55. Byrd-Leifer, C. A.; Block, E. F.; Takeda, K.; Akira, S.; Ding, A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol Eur. J. Immunol. 2001, 31 (8) 2448-57 10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N